Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOUNCE THERAPEUTICS, INC.

(JNCE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

JOUNCE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

06/23/2021 | 04:44pm EDT

Item 5.07. Submission of Matters to a Vote of Security Holders.


Jounce Therapeutics, Inc. (the "Company") held its Annual Meeting of
Stockholders on June 18, 2021. The following is a summary of the matters voted
on at that meeting.
(a) The stockholders of the Company elected J. Duncan Higgons, Robert Iannone,
M.D., M.S.C.E. and Luisa Salter-Cid, Ph.D. as Class I directors, each for a
three-year term ending at the annual meeting of stockholders to be held in 2024
and until his or her successor has been duly elected and qualified. The results
of the stockholders' vote with respect to the election of the Class I directors
were as follows:
Name                                 Votes For       Votes Withheld        Broker Non-Votes
J. Duncan Higgons                    31,777,408        10,873,423             4,163,492
Robert Iannone, M.D., M.S.C.E.       30,977,227        11,673,604             4,163,492
Luisa Salter-Cid, Ph.D.              42,584,638          66,193               4,163,492


(b) The stockholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. The results of the stockholders' vote with respect to such ratification were as follows:

     For            Against        Abstain        Broker Non-Votes
  41,124,791        38,600         16,355                -


--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about JOUNCE THERAPEUTICS, INC.
07:01aJounce Therapeutics Reports Second Quarter 2021 Financial Results
GL
06:39aJOUNCE THERAPEUTICS, INC. : Results of Operations and Financial Condition, Finan..
AQ
07/29Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Hos..
GL
07/07JOUNCE THERAPEUTICS : to Participate in William Blair's Biotech Focus Conference
AQ
06/25JOUNCE THERAPEUTICS, INC.(NASDAQGS : JNCE) dropped from Russell 2000 Value-Defen..
CI
06/25JOUNCE THERAPEUTICS, INC.(NASDAQGS : JNCE) dropped from Russell 2000 Defensive I..
CI
06/23JOUNCE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders ..
AQ
06/23Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Ex..
GL
06/16Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021
GL
06/15UPDATE : Jounce Therapeutics to Get $25 Million From Gilead Sciences After FDA C..
MT
More news